The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Mifegyne     (8S,11R,13S,14S,17S)-11-(4...

Synonyms: Mifeprex, mifepristone, RU-486, RU486, RU-38486, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mifeprex


Psychiatry related information on Mifeprex

  • Mifepristone (RU 486) for Alzheimer's disease [7].
  • RU-486 also delayed the latency period but failed to reduce overall tumor incidence when animals were exposed to MPA at 6 weeks after DMBA treatment, indicating that other factors may also control MPA-induced acceleration [8].
  • RESULTS: Patients treated with mifepristone were significantly more likely to achieve response, defined as a 30% reduction in the Brief Psychiatric Rating Scale (BPRS) [9].
  • CONCLUSIONS: In contrast to our earlier report of positive effects in bipolar disorder, these data suggest that the GR-antagonist mifepristone has no effect on neurocognitive function or symptoms in this group of patients with schizophrenia [10].
  • CYP3A9 mRNA levels were highest in food-deprived animals, whereas RU486 inhibited CYP3A9 mRNA expression and suppressed the induction effect of food deprivation [11].

High impact information on Mifeprex


Chemical compound and disease context of Mifeprex


Biological context of Mifeprex


Anatomical context of Mifeprex


Associations of Mifeprex with other chemical compounds


Gene context of Mifeprex


Analytical, diagnostic and therapeutic context of Mifeprex


  1. Effects of RU486 on HIV-1 replication. Soudeyns, H., Wainberg, M.A. Nat. Med. (1997) [Pubmed]
  2. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Horwitz, K.B. Endocr. Rev. (1992) [Pubmed]
  3. Successful mifepristone treatment of recurrent, inoperable meningioma. Haak, H.R., de Keizer, R.J., Hagenouw-Taal, J.C., van Seters, A.P., Vielvoye, G.J., van Dulken, H. Lancet (1990) [Pubmed]
  4. RU 486 administration in a child with Cushing's syndrome. Beaufrère, B., de Parscau, L., Chatelain, P., Morel, Y., Aguercif, M., François, R. Lancet (1987) [Pubmed]
  5. Induction of labour with mifepristone after intrauterine fetal death. Cabrol, D., Bouvier D'Yvoire, M., Mermet, E., Cedard, L., Sureau, C., Baulieu, E.E. Lancet (1985) [Pubmed]
  6. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Goyeneche, A.A., Carón, R.W., Telleria, C.M. Clin. Cancer Res. (2007) [Pubmed]
  7. Mifepristone (RU 486) for Alzheimer's disease. Pomara, N., Doraiswamy, P.M., Tun, H., Ferris, S. Neurology (2002) [Pubmed]
  8. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Benakanakere, I., Besch-Williford, C., Schnell, J., Brandt, S., Ellersieck, M.R., Molinolo, A., Hyder, S.M. Clin. Cancer Res. (2006) [Pubmed]
  9. Mifepristone versus Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression. Debattista, C., Belanoff, J., Glass, S., Khan, A., Horne, R.L., Blasey, C., Carpenter, L.L., Alva, G. Biol. Psychiatry (2006) [Pubmed]
  10. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Gallagher, P., Watson, S., Smith, M.S., Ferrier, I.N., Young, A.H. Biol. Psychiatry (2005) [Pubmed]
  11. Differential inducibility of specific mRNA corresponding to five CYP3A isoforms in female rat liver by RU486 and food deprivation: comparison with protein abundance and enzymic activities. Cheesman, M.J., Reilly, P.E. Biochem. Pharmacol. (1998) [Pubmed]
  12. Early pregnancy termination with mifepristone and misoprostol in the United States. Spitz, I.M., Bardin, C.W., Benton, L., Robbins, A. N. Engl. J. Med. (1998) [Pubmed]
  13. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. Peyron, R., Aubény, E., Targosz, V., Silvestre, L., Renault, M., Elkik, F., Leclerc, P., Ulmann, A., Baulieu, E.E. N. Engl. J. Med. (1993) [Pubmed]
  14. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Vegeto, E., Allan, G.F., Schrader, W.T., Tsai, M.J., McDonnell, D.P., O'Malley, B.W. Cell (1992) [Pubmed]
  15. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. Glasier, A., Thong, K.J., Dewar, M., Mackie, M., Baird, D.T. N. Engl. J. Med. (1992) [Pubmed]
  16. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). van der Lely, A.J., Foeken, K., van der Mast, R.C., Lamberts, S.W. Ann. Intern. Med. (1991) [Pubmed]
  17. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Beck, C.A., Weigel, N.L., Moyer, M.L., Nordeen, S.K., Edwards, D.P. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  18. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Refaeli, Y., Levy, D.N., Weiner, D.B. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  19. Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies. Elashry-Stowers, D., Zava, D.T., Speers, W.C., Edwards, D.P. Cancer Res. (1988) [Pubmed]
  20. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells. Sridhar, S., Ali, A.A., Liang, Y., El Etreby, M.F., Lewis, R.W., Kumar, M.V. Cancer Res. (2001) [Pubmed]
  21. The progesterone antagonist RU 486. A potential new contraceptive agent. Nieman, L.K., Choate, T.M., Chrousos, G.P., Healy, D.L., Morin, M., Renquist, D., Merriam, G.R., Spitz, I.M., Bardin, C.W., Baulieu, E.E. N. Engl. J. Med. (1987) [Pubmed]
  22. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. Schmidt, P.J., Nieman, L.K., Grover, G.N., Muller, K.L., Merriam, G.R., Rubinow, D.R. N. Engl. J. Med. (1991) [Pubmed]
  23. Receptors bound to antiprogestin from abortive complexes with hormone responsive elements. Guiochon-Mantel, A., Loosfelt, H., Ragot, T., Bailly, A., Atger, M., Misrahi, M., Perricaudet, M., Milgrom, E. Nature (1988) [Pubmed]
  24. Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching. Jabara, H.H., Brodeur, S.R., Geha, R.S. J. Clin. Invest. (2001) [Pubmed]
  25. Mifepristone (RU 486) and second-trimester termination. Urquhart, D.R., Templeton, A.A. Lancet (1987) [Pubmed]
  26. Glucocorticoid-mediated control of the activation and clonal deletion of peripheral T cells in vivo. Gonzalo, J.A., González-García, A., Martínez, C., Kroemer, G. J. Exp. Med. (1993) [Pubmed]
  27. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. Chaisson, M.L., Brooling, J.T., Ladiges, W., Tsai, S., Fausto, N. J. Clin. Invest. (2002) [Pubmed]
  28. Mineralocorticoids, hypertension, and cardiac fibrosis. Young, M., Fullerton, M., Dilley, R., Funder, J. J. Clin. Invest. (1994) [Pubmed]
  29. Antifertility actions of the progesterone antagonist RU 486 include direct inhibition of placental hormone secretion. Das, C., Catt, K.J. Lancet (1987) [Pubmed]
  30. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix. Gupta, J.K., Johnson, N. Lancet (1990) [Pubmed]
  31. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. Meyer, M.E., Pornon, A., Ji, J.W., Bocquel, M.T., Chambon, P., Gronemeyer, H. EMBO J. (1990) [Pubmed]
  32. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Cronstein, B.N., Kimmel, S.C., Levin, R.I., Martiniuk, F., Weissmann, G. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  33. Identification of a negative regulatory function for steroid receptors. McDonnell, D.P., Vegeto, E., O'Malley, B.W. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  34. Glucocorticoids downregulate cyclooxygenase-1 gene expression and prostacyclin synthesis in fetal pulmonary artery endothelium. Jun, S.S., Chen, Z., Pace, M.C., Shaul, P.W. Circ. Res. (1999) [Pubmed]
  35. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. Raaijmakers, H.C., Versteegh, J.E., Uitdehaag, J.C. J. Biol. Chem. (2009) [Pubmed]
  36. Phenotypic consequences of lung-specific inducible expression of FGF-3. Zhao, B., Chua, S.S., Burcin, M.M., Reynolds, S.D., Stripp, B.R., Edwards, R.A., Finegold, M.J., Tsai, S.Y., DeMayo, F.J. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  37. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Scheinman, R.I., Gualberto, A., Jewell, C.M., Cidlowski, J.A., Baldwin, A.S. Mol. Cell. Biol. (1995) [Pubmed]
  38. Influenza virus infection induces metallothionein gene expression in the mouse liver and lung by overlapping but distinct molecular mechanisms. Ghoshal, K., Majumder, S., Zhu, Q., Hunzeker, J., Datta, J., Shah, M., Sheridan, J.F., Jacob, S.T. Mol. Cell. Biol. (2001) [Pubmed]
  39. Steroid Receptor Coactivator-3 and Activator Protein-1 Coordinately Regulate the Transcription of Components of the Insulin-Like Growth Factor/AKT Signaling Pathway. Yan, J., Yu, C.T., Ozen, M., Ittmann, M., Tsai, S.Y., Tsai, M.J. Cancer Res. (2006) [Pubmed]
  40. p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. Ito, K., Jazrawi, E., Cosio, B., Barnes, P.J., Adcock, I.M. J. Biol. Chem. (2001) [Pubmed]
  41. Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice. Han, S.J., Tsai, S.Y., Tsai, M.J., O'Malley, B.W. Endocrinology (2007) [Pubmed]
  42. Antiglucocorticosteroid effects suggest why steroid hormone is required for receptors to bind DNA in vivo but not in vitro. Groyer, A., Schweizer-Groyer, G., Cadepond, F., Mariller, M., Baulieu, E.E. Nature (1987) [Pubmed]
  43. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Rodger, M.W., Baird, D.T. Lancet (1987) [Pubmed]
  44. Postcoital contraception with mifepristone. Glasier, A., Thong, K.J., Dewar, M., Mackie, M., Baird, D.T. Lancet (1991) [Pubmed]
  45. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Norman, J.E., Thong, K.J., Baird, D.T. Lancet (1991) [Pubmed]
  46. RU486 (mifepristone): mechanisms of action and clinical uses. Cadepond, F., Ulmann, A., Baulieu, E.E. Annu. Rev. Med. (1997) [Pubmed]
WikiGenes - Universities